Examining the impacts of pharmacist authority to administer drugs by injection on timely denosumab dosing
Description: Denosumab is an injection given every six months to prevent fractures in men and women with osteoporosis. However, delaying or stopping denosumab therapy can increase the risk of vertebral fractures. Only doctors or nurses could administer denosumab until recently, so patients typically had to bring the drug after picking it up at the pharmacy. We found that many patients delayed or missed denosumab injections, despite the potential worsening of health and fracture risks. Due to the COVID-19 pandemic, we saw a drop in patients receiving denosumab therapy on time with shifts to virtual care and disruptions to healthcare services. Pharmacists, who are easily accessible, have the potential to improve timely administration of denosumab. Yet their authority to administer drugs by injections (AADI), including denosumab, varies across Canada: pharmacists in Alberta have had unrestricted AADI, whereas in Ontario, AADI applied only for education purposes until July 2023. My research will compare the proportion of patients who receive denosumab on time by province over time, and examine the benefit of pharmacist AADI on timely denosumab administration during the pandemic. Pharmacist AADI can enable patients to receive denosumab at the pharmacy when picking up their drug. Better on-time denosumab therapy with pharmacist AADI will lessen health and economic consequences (e.g. pain, disability, early deaths) associated with fractures due to osteoporosis.
Amount: CA$27,000
Funding type: fellowship
Funder scheme: Master's Award: Canada Graduate Scholarships
Start date: 2024-09-01
End date: 2025-08-31
Investigator: Yuna Choi (lead)
Institution: University of Toronto
Subfield: Pharmacy
Field: Health Professions
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: 194771_1
OpenAlex ID: G2100403081
